In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system.
about
Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needsThe dynamic behavior of storage organelles in developing cereal seeds and its impact on the production of recombinant proteinsProduction of biologically active recombinant human factor H in PhyscomitrellaRapid high yield production of different glycoforms of Ebola virus monoclonal antibodyHuman IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationProduction of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons.On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity.A new glycoengineered insect cell line with an inducibly mammalianized protein N-glycosylation pathway.Cost-effective production of a vaginal protein microbicide to prevent HIV transmission.Moss-made pharmaceuticals: from bench to bedside.Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).Production of therapeutic antibodies with controlled fucosylation.Plant-derived vaccines and other therapeutics produced in contained systems.Optimizing therapeutic antibody function: progress with Fc domain engineering.Evolution of plant-made pharmaceuticals.Glycoprotein production in moss bioreactors.IgG-Fc glycoengineering in non-mammalian expression hostsGlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.Glycans as targets for therapeutic antitumor antibodies.The potential of Physcomitrella patens as a platform for the production of plant-based vaccines.Glyco-engineering for biopharmaceutical production in moss bioreactors.Photobioreactors with internal illumination - A survey and comparison.From hybridomas to a robust microalgal-based production platform: molecular design of a diatom secreting monoclonal antibodies directed against the Marburg virus nucleoprotein.In Response to: 'Impact of Glycosylation on Effector Functions of Therapeutic IgG' (Pharmaceuticals 2010, 3, 146-157).Humanizing glycosylation pathways in eukaryotic expression systems.A red light-controlled synthetic gene expression switch for plant systems.Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors.In planta protein sialylation through overexpression of the respective mammalian pathway.An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice.N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans.Application of Lectin Array Technology for Biobetter Characterization: Its Correlation with FcγRIII Binding and ADCC.Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants.Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans.Multiplexed, targeted gene editing in Nicotiana benthamiana for glyco-engineering and monoclonal antibody production.Contained Molecular Farming Using Plant Cell and Tissue Cultures
P2860
Q26795434-1E2D57B8-570F-4BDC-89D7-30B8729633E0Q26853066-4703CDB5-9082-444F-904F-739B10FFA12FQ28290970-3FD2A95A-383A-4AB4-9BEF-A3520537B2ADQ28743509-D5AB576C-BD82-41C2-8149-D78F4D76661BQ30360964-E5CC659A-0E33-4ACA-BE28-A05F99F137CEQ33501332-E5772119-A9CF-4787-B774-6D573C511E99Q35002326-011851FF-AF65-4F00-A9DA-84029BFA95E3Q35232342-BF0C4991-63D9-495E-8E86-E207FC669875Q35703121-34362D3C-BF23-45F7-8F35-E85D8FB9F7ADQ36499053-17A8C92E-27A2-44F4-85CF-71C7AF9ED6C8Q36530505-82766538-49B7-444E-B4FC-54480A0331E5Q37138255-A6C88083-34DD-435B-A82D-67AB3FE5727DQ37672128-4E0D4E3D-12E1-474B-AF05-EEB0C941D169Q37776718-68E13085-3144-4664-934E-501A349ED727Q37804830-D381FA78-869E-4AE1-967D-E02840094EE9Q37891688-59D4A2ED-82A5-4474-A135-A63D79BDFBF2Q37940883-76A6A5EA-A888-4A80-8930-D9534F0BD087Q38013479-63CB46FA-03E1-4C25-B012-DC4F259D339CQ38028654-3C59288A-D93C-41E5-B4AF-1EE96DB59E66Q38034815-8679D372-6ABD-40C9-8644-4971F2843D50Q38176986-91D70594-443F-496B-AF8F-80681341210EQ38234961-2B91F20E-4575-46E0-A0C2-AB33337453E2Q38397295-82FC4B60-4DE4-474E-87B1-0BA2F208FAF4Q38696255-D668DB34-B174-4C0E-BE99-4CE2EFE0C91BQ38974353-7C671C86-0D94-487E-A303-B0D46AD78FA7Q39006079-04AAE6C6-540A-4286-965D-B3B48C2049FBQ39262491-A2A9FFD2-58D3-4182-B4EE-91CA8D5A6B36Q39337108-250F2C64-00A6-4F1B-A0A9-8889BB0ECCAAQ39454978-DFF14F37-5A71-4E72-93EF-25A117B4C484Q40602343-286BAE27-6384-42A5-A051-8CB939ECE93CQ41725365-377AC846-D736-481C-B87A-400E821A9298Q42258662-E874A02B-8DF7-4C9C-8DD0-3CFAEEA94479Q42293231-7B225616-A99D-4EC6-B356-3A7F7884A100Q45716164-B122DBE1-C0DD-4073-A3EC-E37C72E389E4Q46916838-9D217BD8-417B-4C8F-BE55-FC6B1A463176Q47929562-E630D374-D2CC-4D0E-AE66-8FD2C9762E5AQ57694977-3B4714A4-3EC2-43D8-B54D-845480D50FE7
P2860
In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
In vivo glyco-engineered antib ...... n-mammalian expression system.
@en
In vivo glyco-engineered antib ...... n-mammalian expression system.
@nl
type
label
In vivo glyco-engineered antib ...... n-mammalian expression system.
@en
In vivo glyco-engineered antib ...... n-mammalian expression system.
@nl
prefLabel
In vivo glyco-engineered antib ...... n-mammalian expression system.
@en
In vivo glyco-engineered antib ...... n-mammalian expression system.
@nl
P2093
P356
P1476
In vivo glyco-engineered antib ...... n-mammalian expression system.
@en
P2093
Christian Stemmer
Cornelia Schwager
Evelyne Janzek
Geert C Mudde
Gilbert Gorr
Johannes Stadlmann
Manfred Schuster
Susanne Wiederkum
Wolfgang Jost
P304
P356
10.1002/BIOT.200600255
P577
2007-06-01T00:00:00Z